The Lewis lab research interests are focused on the development of new PET radiopharmaceuticals for the diagnosis and treatment of cancer. Our work incorporates 89Zr, 18F, 11C, and other nonstandard nuclides, with an emphasis on designing novel PET agents for cancer imaging. Our research program is a molecular-imaging-based program focused on the targeting of nonstandard nuclides as well as the development of small- and biomolecule-based agents and their clinical translation. A few examples of our work are given below.
Jason S. Lewis, PhD
Director, Center for Molecular Imaging and Nanotechnology
Research FocusRadiochemist Jason Lewis develops radiopharmaceuticals for the imaging and therapy of cancer.
- PhD, The University of Kent (UK)
- Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC status with 89Zr-transferrin imaging. Nat Med. 2012 Oct;18(10):1586-91. doi: 10.1038/nm.2935. Epub 2012 Sep 23.
- Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012 Apr;2(4):320-7. doi: 10.1158/2159-8290.CD-11-0316. Epub 2012 Mar 31.
- Berson-Yalow Award, Society of Nuclear Medicine and Molecular Imaging (2013)